Search Results - "SCHLÜNTZ, CAMILLA"

Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes by Johansen, Nicklas J., Dejgaard, Thomas F., Lund, Asger, Schlüntz, Camilla, Hartmann, Bolette, Holst, Jens J., Vilsbøll, Tina, Andersen, Henrik U., Knop, Filip K.

“…Aim To evaluate the efficacy of the short‐acting glucagon‐like peptide‐1 receptor agonist, exenatide, added to insulin therapy in type 1 diabetes on bone…”
Get full text

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial by Johansen, Nicklas J, Dejgaard, Thomas F, Lund, Asger, Schlüntz, Camilla, Frandsen, Christian S, Forman, Julie L, Wewer Albrechtsen, Nicolai J, Holst, Jens J, Pedersen-Bjergaard, Ulrik, Madsbad, Sten, Vilsbøll, Tina, Andersen, Henrik U, Knop, Filip K

“…In type 2 diabetes, long-acting GLP-1 receptor agonists lower fasting plasma glucose and improve glycaemic control via their insulinotropic and glucagonostatic…”
Get full text

1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial by JOHANSEN, NICKLAS J., DEJGAARD, THOMAS F., LUND, ASGER, SCHLÜNTZ, CAMILLA, LARSEN, EMIL LIST, POULSEN, HENRIK E., GØTZE, JENS P., MØLLER, HOLGER, VILSBØLL, TINA, ANDERSEN, HENRIK U., KNOP, FILIP K.

“…In type 2 diabetes, some glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events. Whether GLP-1RAs have any…”
Get full text

Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial by Johansen, Nicklas J., Dejgaard, Thomas F., Lund, Asger, Schlüntz, Camilla, Larsen, Emil L., Poulsen, Henrik E., Goetze, Jens P., Møller, Holger J., Vilsbøll, Tina, Andersen, Henrik U., Knop, Filip K.

“…Aims To investigate the effect of adding the short‐acting glucagon‐like peptide 1 receptor agonist (GLP‐1RA) exenatide to insulin treatment on markers of…”
Get full text